company background image
ACLX

Arcellx NasdaqGS:ACLX Stock Report

Last Price

US$19.97

Market Cap

US$875.0m

7D

8.8%

1Y

n/a

Updated

28 Sep, 2022

Data

Company Financials +
ACLX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ACLX Stock Overview

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.

Arcellx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arcellx
Historical stock prices
Current Share PriceUS$19.97
52 Week HighUS$26.91
52 Week LowUS$6.04
Beta0
1 Month Change19.08%
3 Month Change10.45%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO18.87%

Recent News & Updates

Aug 23

Arcellx: The Best Is Yet To Come

Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology. This data will be out sometime next year. I covered Arcellx (ACLX) at its IPO in January. Arcellx is a clinical stage biopharma developing cancer immunotherapies. It has a novel D-Domain technology that makes traditional cell therapies like CAR-Ts safer and more efficacious. Recent ASCO data showed that its "more traditional" CAR-T candidate still bested Johnson & Johnson and Legend Biotech, including the former's Carvykti, an approved product. "Pretty much any way you slice the updated data, CART-ddBCMA's efficacy outcomes are in line with the class leader, cilta-cel (Carvykti)-best response, [minimal residual disease] negativity, and measures of durability," SVB Securities wrote, according to Fierce. The patient population was arguably more difficult to treat, with a high rate of extramedullary involvement, and unlike Carvykti, which has a black box warning for cytokine release syndrome, ACLX seemed safer. ACLX' D-Domains are used in chimeric antigen receptor ((CAR)) constructs, and result in "higher transduction efficiency, high cell surface expression, and low tonic signaling." The first two points relate to the molecule's improvement of CAR-T efficacy and the last to its increased safety. Transduction is the viral ability to transfer genetic material; cell surface expression of CAR-Ts are enhanced through the simpler structures of the D-Domain; and tonic signaling refers to activation of T cells, which may cause unwanted immune feedback. Arcellx has these D-Domains that are small, fully synthetic, hydrophobic and stable binding agents, unlike traditional binders that are biologic, single-chain variable fragment (scFv) binding CAR T cells that have narrow applicability and high toxicity. These D-Domains can be produced in large batches with great consistency and tailored to each cancer situation. The company is quite early stage, with only preliminary data available from one of its two ongoing phase 1 trials. This is the company's first product candidate, CART-ddBCMA. It targets the B-cell maturation antigen (BCMA), and is being evaluated in a Phase 1 proof-of-concept study "iMMagine" for relapsed or refractory (r/r) multiple myeloma ((MM)) in patients with either minimal response or disease progression within 60 days of last treatment. The study "demonstrated 100% overall response rate and deep durability." The company plans to jump directly to a pivotal study next year. Prelim data has shown good safety, with only one grade 3 CR and a decent toxicity profile. The data compares very favorably to two other CAR-T programs, LEGEND-2, and CERTITUDE-1 from JNJ. Their data is available here. You will note that sample sizes were not widely divergent in strength, yet ACLX did a marginally better job with both ORR and CR. Its other assets are all earlier, preclinical stage product candidates. Among scores of CAR-T companies and probably hundreds of cell therapy companies, what makes newbie Arcellx stand out? According to the company, they have the first "controllable CAR-T" in the clinic. This is the asset where they dosed the first patient this year. According to the company, this has "a linking protein that would enable physicians to control the dose and frequency of CAR-T cell therapy after it's been administered." Already its first trial with data from a more traditional CAR-T has beat the "class-leader" in BCMA-targeted therapy, Janssen's cilta-cel. These are among some of the reasons ACLX is upbeat despite a late entry. This, and the huge demand for life-changing CAR-T therapies that's in the market right now. How does the controllable technology work? CART is a highly efficacious treatment with great benefit, however the disease relapses as the cancer mutates. Arcellx has a two-part therapy called SparX which latch on to cancer cells and draws the CAR-T to that cell. If the cancer mutates, Arcellx simply needs to infuse the patient with a new batch of these SparX proteins, and they will latch on to the mutated cancer cell, drawing the CAR-Ts to them once again.

Aug 15

Arcellx GAAP EPS of -$0.88

Arcellx press release (NASDAQ:ACLX): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million

Aug 03

Arcellx down 9% on day lock-up period ends

Arcellx (NASDAQ:ACLX) shares are down 9% in late Wednesday afternoon trading. Today marks the end of the company's IPO lock-up period. Volume is slightly above the daily average of ~305.2K. As of 325p ET, ~401.4K shares had traded hands. Arcellx is focused on cancer immunotherapies. Its lead  candidate is CART-ddBCMA, in phase 1 for relapsed or refractory (r/r) multiple myeloma. The company made its market debut in February. Arcellx (ACLX) was recently named a new buy by Canaccord Genuity.

Jun 27
We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ACLXUS BiotechsUS Market
7D8.8%2.9%-2.0%
1Yn/a-24.2%-20.3%

Return vs Industry: Insufficient data to determine how ACLX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ACLX performed against the US Market.

Price Volatility

Is ACLX's price volatile compared to industry and market?
ACLX volatility
ACLX Average Weekly Movement9.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ACLX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ACLX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201478Rami Elghandourhttps://arcellx.com

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.

Arcellx, Inc. Fundamentals Summary

How do Arcellx's earnings and revenue compare to its market cap?
ACLX fundamental statistics
Market CapUS$874.98m
Earnings (TTM)-US$102.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACLX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$102.24m
Earnings-US$102.24m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ACLX perform over the long term?

See historical performance and comparison